TY - JOUR
T1 - Response of human REV1 to different DNA damage
T2 - Preferential dCMP insertion opposite the lesion
AU - Zhang, Yanbin
AU - Wu, Xiaohua
AU - Rechkoblit, Olga
AU - Geacintov, Nicholas E.
AU - Taylor, John Stephen
AU - Wang, Zhigang
N1 - Funding Information:
We thank Fenghuan Yuan for technical assistance in the purification of human REV1 protein. This work was supported by a New Investigator Award in Toxicology from Burroughs Wellcome Fund (Z.W.) and NIH grants CA40463 (J.-S.T.) and CA20851 (N.E.G.).
PY - 2002/4/1
Y1 - 2002/4/1
N2 - REV1 functions in the DNA polymerase ζ mutagenesis pathway. To help understand the role of REV1 in lesion bypass, we have examined activities of purified human REV1 opposite various template bases and several different DNA lesions. Lacking a 3′→5′ proofreading exonuclease activity, purified human REV1 exhibited a DNA polymerase activity on a repeating template G sequence, but catalyzed nucleotide insertion with 6-fold lower efficiency opposite a template A and 19-27-fold lower efficiency opposite a template T or C. Furthermore, dCMP insertion was greatly preferred regardless of the specific template base. Human REV1 inserted a dCMP efficiently opposite a template 8-oxoguanine, (+)-trans-anti-benzo[a]pyrene-N2-dG, (-)-trans-anti-benzo[a]pyrene-N2-dG and 1,N6-ethenoadenine adducts, very inefficiently opposite an acetylamino-fluorene-adducted guanine, but was unresponsive to fluorene-adducted guanine, but was unresponsive to a template TT dimer or TT (6-4) photoproduct. Surprisingly, the REV1 specificity of nucleotide insertion was very similar in response to different DNA lesions with greatly preffered C insertion and least frequent A insertion. By combining the dCMP insertion activity of human REV1 with the extension synthesis activity of human polymerase κ, bypass of the trans-anti-benzo[a]pyrene-N2-dG adducts and the 1,N6-ethenoadenine lesion was achieved by the two-polymerase two-step mechanism. These results suggest that human REV1 is a specialized DNA polymerase that may contribute to dCMP insertion opposite many types of DNA damage during lesion bypass.
AB - REV1 functions in the DNA polymerase ζ mutagenesis pathway. To help understand the role of REV1 in lesion bypass, we have examined activities of purified human REV1 opposite various template bases and several different DNA lesions. Lacking a 3′→5′ proofreading exonuclease activity, purified human REV1 exhibited a DNA polymerase activity on a repeating template G sequence, but catalyzed nucleotide insertion with 6-fold lower efficiency opposite a template A and 19-27-fold lower efficiency opposite a template T or C. Furthermore, dCMP insertion was greatly preferred regardless of the specific template base. Human REV1 inserted a dCMP efficiently opposite a template 8-oxoguanine, (+)-trans-anti-benzo[a]pyrene-N2-dG, (-)-trans-anti-benzo[a]pyrene-N2-dG and 1,N6-ethenoadenine adducts, very inefficiently opposite an acetylamino-fluorene-adducted guanine, but was unresponsive to fluorene-adducted guanine, but was unresponsive to a template TT dimer or TT (6-4) photoproduct. Surprisingly, the REV1 specificity of nucleotide insertion was very similar in response to different DNA lesions with greatly preffered C insertion and least frequent A insertion. By combining the dCMP insertion activity of human REV1 with the extension synthesis activity of human polymerase κ, bypass of the trans-anti-benzo[a]pyrene-N2-dG adducts and the 1,N6-ethenoadenine lesion was achieved by the two-polymerase two-step mechanism. These results suggest that human REV1 is a specialized DNA polymerase that may contribute to dCMP insertion opposite many types of DNA damage during lesion bypass.
UR - http://www.scopus.com/inward/record.url?scp=0036529562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036529562&partnerID=8YFLogxK
U2 - 10.1093/nar/30.7.1630
DO - 10.1093/nar/30.7.1630
M3 - Review article
C2 - 11917024
AN - SCOPUS:0036529562
SN - 0305-1048
VL - 30
SP - 1630
EP - 1638
JO - Nucleic acids research
JF - Nucleic acids research
IS - 7
ER -